High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.
作者信息
Ruddy Jake A, Connolly Caoilfhionn Marie, Boyarsky Brian J, Werbel William A, Christopher-Stine Lisa, Garonzik-Wang Jacqueline, Segev Dorry L, Paik Julie J
机构信息
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
Ann Rheum Dis. 2021 Oct;80(10):1351-1352. doi: 10.1136/annrheumdis-2021-220656. Epub 2021 May 24.
Abstract
摘要
相似文献
1
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.风湿性和肌肉骨骼疾病患者对两剂严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗的高抗体反应。
Ann Rheum Dis. 2021 Oct;80(10):1351-1352. doi: 10.1136/annrheumdis-2021-220656. Epub 2021 May 24.
2
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.利妥昔单抗治疗患者的新型冠状病毒2型疫苗接种：体液免疫受损但细胞免疫反应可诱导的证据
Ann Rheum Dis. 2021 Oct;80(10):1355-1356. doi: 10.1136/annrheumdis-2021-220408. Epub 2021 May 6.
3
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.利妥昔单抗而非其他抗风湿疗法，与风湿性疾病患者对SARS-CoV-2疫苗的血清学反应受损有关。
Ann Rheum Dis. 2021 Oct;80(10):1357-1359. doi: 10.1136/annrheumdis-2021-220604. Epub 2021 May 11.
4
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.BNT162b2 mRNA COVID-19 疫苗在成年自身免疫性炎症性风湿病患者和普通人群中的免疫原性和安全性：一项多中心研究。
Ann Rheum Dis. 2021 Oct;80(10):1330-1338. doi: 10.1136/annrheumdis-2021-220647. Epub 2021 Jun 14.
5
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.炎症性风湿病患者接种两剂辉瑞 SARS-CoV-2 mRNA 疫苗后的疾病活动和体液反应。
Ann Rheum Dis. 2021 Oct;80(10):1317-1321. doi: 10.1136/annrheumdis-2021-220503. Epub 2021 Jun 18.
6
Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.关于“利妥昔单抗治疗患者的新型冠状病毒2疫苗接种：体液免疫受损但细胞免疫可诱导的证据”的通信
Ann Rheum Dis. 2021 Oct;80(10):e162. doi: 10.1136/annrheumdis-2021-220756. Epub 2021 Jul 16.
7
Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.一名类风湿性关节炎患者接种BNT162b2加强针成功，且最初抗体反应呈阴性。
Ann Rheum Dis. 2021 Oct;80(10):1361-1362. doi: 10.1136/annrheumdis-2021-220834. Epub 2021 Jun 24.
8
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.在接受利妥昔单抗治疗的患者中接种 SARS-CoV-2 疫苗：B 细胞在 T 细胞介导的免疫存在下促进体液免疫反应。
Ann Rheum Dis. 2021 Oct;80(10):1345-1350. doi: 10.1136/annrheumdis-2021-220781. Epub 2021 Jul 20.
9
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.未治疗、常规治疗和抗细胞因子治疗的免疫介导性炎症性疾病患者的 SARS-CoV-2 疫苗反应。
Ann Rheum Dis. 2021 Oct;80(10):1312-1316. doi: 10.1136/annrheumdis-2021-220461. Epub 2021 May 6.
10
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.在一项单中心队列研究中，慢性炎症性疾病和免疫抑制治疗患者的抗 SARS-CoV-2 mRNA 疫苗的免疫原性和安全性。
Ann Rheum Dis. 2021 Oct;80(10):1306-1311. doi: 10.1136/annrheumdis-2021-220272. Epub 2021 Mar 24.
引用本文的文献
1
A third COVID-19 vaccine dose in kidney transplant recipients induces antibody response to vaccine and Omicron variants but shows limited Ig subclass switching.肾移植受者接种第三剂新冠病毒疫苗可诱导对疫苗和奥密克戎变异株的抗体反应，但免疫球蛋白亚类转换有限。
Microbiol Spectr. 2025 Mar 4;13(3):e0219024. doi: 10.1128/spectrum.02190-24. Epub 2025 Jan 31.
2
Immunogenicity of an Inactivated COVID-19 Vaccine in People Living with HIV in Guangxi, China: A Prospective Cohort Study.中国广西 HIV 感染者的新型冠状病毒灭活疫苗免疫原性：一项前瞻性队列研究。
Viruses. 2024 Sep 18;16(9):1481. doi: 10.3390/v16091481.
3
Prevalence and Risk Factors of Postacute Sequelae of COVID-19 in Adults With Systemic Autoimmune Rheumatic Diseases.COVID-19 后急性后遗症在患有系统性自身免疫性风湿病的成年人中的流行情况和危险因素。
J Rheumatol. 2024 Sep 1;51(9):928-933. doi: 10.3899/jrheum.2023-1212.
4
Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases.生物制剂和糖皮质激素治疗会损害自身免疫性炎症性风湿病患者对 SARS-CoV-2 mRNA 疫苗的中期免疫原性。
Eur J Med Res. 2024 Jan 5;29(1):28. doi: 10.1186/s40001-023-01620-7.
5
Long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases: The ERN-ReCONNET VACCINATE study.罕见和复杂结缔组织病患者新冠病毒疫苗接种的长期结果：ERN-ReCONNET疫苗接种研究
J Transl Autoimmun. 2023 Nov 28;7:100221. doi: 10.1016/j.jtauto.2023.100221. eCollection 2023 Dec.
6
COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases.免疫介导的炎症性疾病中的 COVID-19 疫苗接种与免疫抑制治疗
Vaccines (Basel). 2023 Dec 4;11(12):1813. doi: 10.3390/vaccines11121813.
7
Anti-Interleukin-1 Therapy Does Not Affect the Response to SARS-CoV-2 Vaccination and Infection in Patients with Systemic Autoinflammatory Diseases.抗白细胞介素-1疗法不影响系统性自身炎症性疾病患者对SARS-CoV-2疫苗接种和感染的反应。
J Clin Med. 2023 Dec 8;12(24):7587. doi: 10.3390/jcm12247587.
8
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2.专家共识：影响 COVID-19 预后不良的主要危险因素及其对靶向 SARS-CoV-2 措施的影响。
Viruses. 2023 Jun 27;15(7):1449. doi: 10.3390/v15071449.
9
Virus-Subtype-Specific Cellular and Humoral Immune Response to a COVID-19 mRNA Vaccine in Chronic Kidney Disease Patients and Renal Transplant Recipients.慢性肾脏病患者和肾移植受者对新冠病毒mRNA疫苗的病毒亚型特异性细胞免疫和体液免疫反应
Microorganisms. 2023 Jul 5;11(7):1756. doi: 10.3390/microorganisms11071756.
10
Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy.在接受免疫抑制治疗的炎性风湿性疾病患者中，科兴疫苗（CoronaVac）和BNT162b2疫苗诱导的抗刺突IgG、抗刺突IgA水平及中和抗体活性的比较。
BMC Rheumatol. 2023 Jul 19;7(1):20. doi: 10.1186/s41927-023-00342-x.
本文引用的文献
1
Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.风湿性和肌肉骨骼疾病患者接种两剂严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗后无体液免疫反应：病例系列
Ann Intern Med. 2021 Sep;174(9):1332-1334. doi: 10.7326/M21-1451. Epub 2021 May 25.
2
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.在一项单中心队列研究中，慢性炎症性疾病和免疫抑制治疗患者的抗 SARS-CoV-2 mRNA 疫苗的免疫原性和安全性。
Ann Rheum Dis. 2021 Oct;80(10):1306-1311. doi: 10.1136/annrheumdis-2021-220272. Epub 2021 Mar 24.
3
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.风湿性和肌肉骨骼疾病患者对单剂SARS-CoV-2 mRNA疫苗的抗体反应。
Ann Rheum Dis. 2021 Aug;80(8):1098-1099. doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23.
4
Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation.抗SARS-CoV-2抗体的定量检测：分析与临床评估
J Clin Microbiol. 2021 Mar 19;59(4). doi: 10.1128/JCM.03149-20.
5
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.SARS-CoV-2 mRNA-1273疫苗接种后反应的持久性。
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.
6
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.两种基于 RNA 的新冠候选疫苗的安全性和免疫原性。
N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14.
Zotero 插件